Group One Trading
DAWN

Group One Trading’s Day One Biopharmaceuticals DAWN Stock Holding History

Group One Trading’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-253,143
Closed -$3.57M – 7857
2025
Q4 		$2.36M Buy
+253,143
New +$2.11M ﹤0.01% 2141
2025
Q3 		– Sell
-1,346
Closed -$9.26K – 8529
2025
Q2 		$8.75K Sell
1,346
-3,098
-70% -$21.3K ﹤0.01% 6794
2025
Q1 		$35.2K Buy
+4,444
New +$47.9K ﹤0.01% 5434
2024
Q3 		– Sell
-5,987
Closed -$85.4K – 6758
2024
Q2 		$82.5K Buy
5,987
+982
+20% +$14.4K ﹤0.01% 4113
2024
Q1 		$82.7K Buy
+5,005
New +$74.9K ﹤0.01% 4308
2023
Q4 		– Sell
-2,958
Closed -$35.9K – 7533
2023
Q3 		$36.3K Buy
+2,958
New +$38.6K ﹤0.01% 5391
2023
Q1 		– Sell
-45,586
Closed -$890K – 7331
2022
Q4 		$981K Sell
45,586
-13,537
-23% -$278K ﹤0.01% 2422
2022
Q3 		$1.18M Buy
+59,123
New +$1.26M ﹤0.01% 2394

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Group One Trading's DAWN Position: Q1 2026 in Review

Group One Trading sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 253,143 shares — an estimated $3.57M sold.

Group One Trading first reported a position in DAWN in Q3 2022 and held it in 8 quarters. The position peaked at $2.36M in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Group One Trading reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 253,143 Day One Biopharmaceuticals shares in Q1 2026, an estimated $3.57M.
  • Group One Trading first reported a position in Day One Biopharmaceuticals in Q3 2022 and held it in 8 quarters.
  • Group One Trading's Day One Biopharmaceuticals position peaked at $2.36M in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.